---
title: Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy
  for Pulmonary Arterial Hypertension
date: '2024-01-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38267108/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240125170715&v=2.18.0
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Macitentan and tadalafil FDC significantly improved PVR
  vs monotherapies in PAH patients, with a safety and tolerability profile consistent
  with the individual components. The A DUE study supports M/T FDC as a once-daily,
  single-tablet combination for initial therapy and escalation to double combination
  therapy in patients with PAH. (Clinical Study to Compare the Efficacy and Safety
  of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination
  Therapy ...'
disable_comments: true
---
CONCLUSIONS: Macitentan and tadalafil FDC significantly improved PVR vs monotherapies in PAH patients, with a safety and tolerability profile consistent with the individual components. The A DUE study supports M/T FDC as a once-daily, single-tablet combination for initial therapy and escalation to double combination therapy in patients with PAH. (Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy ...